Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Laboratorio Farmaceutico Erfo SpA's average EBITDA Per Share Growth Rate was 62.30% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 9.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -1.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Laboratorio Farmaceutico Erfo SpA was 9.80% per year. The lowest was -13.30% per year. And the median was -5.25% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Laboratorio Farmaceutico Erfo SpA 3-Year EBITDA Growth Rate Related Terms
MIL:ERFO vs KHC, GIS, HRL: 3-Year EBITDA Growth Rate Comparison
For the Packaged Foods subindustry, Laboratorio Farmaceutico Erfo SpA's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorio Farmaceutico Erfo SpA 3-Year EBITDA Growth Rate vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Laboratorio Farmaceutico Erfo SpA's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Laboratorio Farmaceutico Erfo SpA's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 9.80% mean?
Laboratorio Farmaceutico Erfo SpA (MIL:ERFO) has a 3-Year EBITDA Growth Rate of 9.80% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Laboratorio Farmaceutico Erfo SpA and its competitors. According to the industry distribution chart, Laboratorio Farmaceutico Erfo SpA ranks #781 out of 1663 companies in the Consumer Packaged Goods industry, placing it in the top 47%.
Is Laboratorio Farmaceutico Erfo SpA's 3-Year EBITDA Growth Rate too high?
Laboratorio Farmaceutico Erfo SpA's current 3-Year EBITDA Growth Rate is 9.80%. The Consumer Packaged Goods industry median 3-Year EBITDA Growth Rate is 8.10. Laboratorio Farmaceutico Erfo SpA's value of 9.80% is 21% above this industry median. Based on the distribution chart, Laboratorio Farmaceutico Erfo SpA ranks #781 out of 1663 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, Laboratorio Farmaceutico Erfo SpA has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Laboratorio Farmaceutico Erfo SpA's 3-Year EBITDA Growth Rate compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Laboratorio Farmaceutico Erfo SpA ranks #781 out of 1663 companies for 3-Year EBITDA Growth Rate. This puts Laboratorio Farmaceutico Erfo SpA in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.10. Laboratorio Farmaceutico Erfo SpA's value of 9.80% is 21% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Consumer Packaged Goods company?
The median 3-Year EBITDA Growth Rate among Consumer Packaged Goods companies is 8.10, based on 1,663 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorio Farmaceutico Erfo SpA's current 3-Year EBITDA Growth Rate of 9.80% is 21% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Laboratorio Farmaceutico Erfo SpA and its competitors. For the Consumer Packaged Goods industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorio Farmaceutico Erfo SpA's current 3-Year EBITDA Growth Rate is 9.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorio Farmaceutico Erfo SpA stock overvalued right now?
Based on GuruFocus' analysis, Laboratorio Farmaceutico Erfo SpA (MIL:ERFO) is currently considered Significantly Undervalued. The stock's GF Value™ is €2.16, compared to a current price of €1.13 — trading 47.9% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 9.80% and 21% above the Consumer Packaged Goods industry median of 8.10. Laboratorio Farmaceutico Erfo SpA's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Laboratorio Farmaceutico Erfo SpA (MIL:ERFO), the current 3-Year EBITDA Growth Rate is 9.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorio Farmaceutico Erfo SpA (MIL:ERFO) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorio Farmaceutico Erfo SpA stock appears to be undervalued.
The current stock price of €1.13 is trading 47.9% below its estimated GF Value™ of €2.16.
GuruFocus considers Laboratorio Farmaceutico Erfo SpA to be Significantly Undervalued.
Key valuation signals for MIL:ERFO:
3-Year EBITDA Growth Rate: 9.80%
GF Value™: €2.16 vs. price of €1.13 (47.9% below fair value)
Industry Position: 21% above the Consumer Packaged Goods median (#781 of 1663)
No single metric tells the full story. See the MIL:ERFO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorio Farmaceutico Erfo SpA operates in the nutraceutical sector. The company specializes in formulating and producing food supplements and natural medicines in different forms such as liquids, powders, granules, tablets, and soft gels. Geographically, the company generates a majority of its revenue from Italy followed by Spain, France, Belgium, and other countries.
64GF Score
Get the complete analysis for MIL:ERFO
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:ERFO has been successfully added to your 
